| Affiliation: | 1. Microbiology Insititute of Shaanxi, Xi'an, China Engineering Center of Qinling Mountains Natural Products, Shaanxi Academy of Sciences, Xi'an, China;2. School of Light Industry, Beijing Technology and Business University, Beijing, China;3. Clinical Laboratory, Shaanxi Provincial People's Hospital, Xi'an, China;4. Microbiology Insititute of Shaanxi, Xi'an, China |
| Abstract: | Candida albicans is one of the most common clinical pathogenic microorganisms and it is becoming a serious health threat, particularly to immunocompromised populations. Drug resistance of Candida species has also frequently emerged, and combination therapy for fungal infections has attracted considerable attention. In this study, we established the Qinling Mountains myxobacterial secondary metabolites library and a synergic assay in combination with ketoconazole against C. albicans was introduced for metabolites screening. Two active compounds with synergic anticandidal activities were obtained, which were identified as trans-resveratrol and cis-resveratrol. According to our study, resveratrol can reduce the dosage to 1/64 of ketoconazole as well as itraconazole. Furthermore, synergistic anticandidal activity of resveratrol combined with azoles was verified against a panel of clinical C. albicans isolates, and the combination strategy enhanced the azoles susceptibility of three fluconazole-resistant isolates. These findings suggest that resveratrol enhances the efficacy of azoles and provides a promising application in therapy of C. albicans infection. |
